DSGN•benzinga•
RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2022 by benzinga